Czech National Bank Has $27.95 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• The Czech National Bank has increased its stake in Vertex Pharmaceuticals by 6.4%, now holding 62,770 shares valued at approximately $27.95 million.
• Institutional investors dominate the ownership of Vertex Pharmaceuticals, with 90.96% of the stock owned by these entities, including significant increases from firms like GAMMA Investing LLC and Price T Rowe Associates Inc.
• Vertex Pharmaceuticals reported strong earnings of $4.52 EPS, exceeding expectations, and achieving a revenue of $2.94 billion for the quarter, marking an 11.3% increase compared to the prior year.

Czech National Bank increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,770 shares of the pharmaceutical company's stock after buying an additional 3,790 shares during the period. Czech National Bank's holdings in Vertex Pharmaceuticals were worth $27,945,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in VRTX. GAMMA Investing LLC increased its holdings in Vertex Pharmaceuticals by 60,572.3% during the first quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company's stock worth $1,175,722,000 after buying an additional 2,421,073 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Vertex Pharmaceuticals by 72.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company's stock valued at $1,414,331,000 after purchasing an additional 1,226,527 shares during the last quarter. Nuveen LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter valued at about $484,053,000. Jennison Associates LLC lifted its stake in shares of Vertex Pharmaceuticals by 17.2% during the 1st quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company's stock worth $2,454,373,000 after buying an additional 744,680 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Vertex Pharmaceuticals by 28.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,775,194 shares of the pharmaceutical company's stock worth $860,650,000 after buying an additional 398,460 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Bruce I. Sachs acquired 5,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Down 0.3%

VRTX opened at $393.21 on Tuesday. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.88. The company has a 50-day simple moving average of $421.34 and a 200 day simple moving average of $452.63. The stock has a market capitalization of $100.82 billion, a price-to-earnings ratio of 28.11 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same quarter in the prior year, the business posted ($12.83) earnings per share. Vertex Pharmaceuticals's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of research reports. Evercore ISI cut their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an "outperform" rating for the company in a research note on Thursday, September 11th. Guggenheim cut their target price on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Royal Bank Of Canada cut their target price on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating for the company in a research note on Tuesday, August 5th. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, August 5th. Finally, Wells Fargo & Company upgraded shares of Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 target price for the company in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $496.05.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.